Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Detecting Stigmatizing Language in Clinical Notes with Large Language Models for Addiction Care.

medRxiv : the preprint server for health sciences·2025

Same author

Pesticides in the environment: Degradation routes, pesticide transformation products and ecotoxicological considerations.

The Science of the total environment·2024

Same author

Dyslipidemia and heart failure: current evidence and perspectives of use of statins.

European review for medical and pharmacological sciences·2024

Same author

Magnetic resonance imaging in paediatric ocular and orbital lesions: A pictorial review.

Current problems in diagnostic radiology·2024

Same author

Lipid Profile and Small Dense Low-Density Lipoprotein in Acute Coronary Syndrome Patients: Relationships to Demographic, Clinical, Angiographic, and Therapeutic Variables.

Journal of clinical medicine·2022

Same author

Of "Cotton Balls" and "Owl's eyes".

The Malaysian journal of pathology·2020

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

"Tenecteplase--the best among the equals.".

R K Saran¹, R Sethi, M Nagori

¹Department of Cardiology, CSM Medical University, Lucknow, Uttar Pradesh, India. rksaran@sify.com

Indian Heart Journal

|July 20, 2010

Summary

Tenecteplase offers faster arterial reperfusion and is equivalent to Alteplase for mortality in acute myocardial infarction (MI). This bolus thrombolytic reduces bleeding and transfusion needs, proving effective in prehospital settings.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

Area of Science:

Cardiology
Pharmacology
Biotechnology

Background:

Tenecteplase is a genetically engineered thrombolytic derived from Alteplase.
It features enhanced fibrin specificity and a prolonged half-life compared to Alteplase.

Purpose of the Study:

To evaluate Tenecteplase as a rapid, effective thrombolytic agent for acute myocardial infarction (MI).
To compare Tenecteplase's efficacy and safety against Alteplase and primary angioplasty.

Main Methods:

Analysis of large-scale clinical trials and international registries involving Tenecteplase in acute MI.
Comparison of mortality rates, reperfusion times, bleeding events, and transfusion requirements.

Main Results:

Tenecteplase demonstrates equivalence to front-loaded Alteplase in mortality and allows for bolus administration.
It shows increased potency beyond 4 hours of symptom duration, with significantly reduced major bleeding and transfusion rates.
Prehospital thrombolysis with Tenecteplase is as effective as primary angioplasty.

Conclusions:

Tenecteplase is an evidence-based, effective, and safer thrombolytic option for acute MI, particularly when primary PCI is logistically challenging.
Its properties support faster reperfusion and improved patient outcomes.